Share this publication:
There has been debate on the best treatment regimen for CAP, whether to start treatment with β-lactams, β-lactam β-lactamase inhibitor, macrolides, a combina- tion of the earlier or quinolones, among other less commonly used agents. In this review, an attempt to examine some data on the utilization and importance of respiratory quinolones in the treatment of CAP, and to examine whether quinolones are the same in clinical and microbiological efficacy, shall we stick to seven days of treatment versus shorter duration without compromising outcome?
Are resistance patterns for respiratory quinolones the same, and are there savings as- sociated with using some respiratory quinolones over others? Moreover, are there any differences in mortality when examined as a treatment endpoint, and if there is any differences in speed of recovery for different respiratory quinolones? Do we need to incorporate pharmacokinetics/pharmacodynamics principles in the treatment of CAP, and how to dose antiinfective agents in CAP, opposed to leaving treatment-doses for minimum inhibitory concentration alone?
About the publisher:
iMedPub Limited is a publishing house registered in UK, publishing medical books and journals since 2005. As an open service to doctors and biomedical researchers, it is driven by clinicians and researchers for themselves, while serving the interests of the general public. iMedPub disseminates research in a tiered system, beginning with our specialty books and journals and then working upwards. The grand vision of iMedPub is a world where all medical researchers and health professionals have an equal opportunity to seek, share and create knowledge. As we are a low cost academic publisher we offer the lowest article processing charges of all biomedical journals and publish books free of charges for authors.